Article
Oncology
Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, Yutaka Kawakami
Summary: The study aimed to investigate the safety and efficacy of nivolumab with paclitaxel plus ramucirumab in advanced gastric cancer, showing promising antitumor activity with manageable toxicities, suggesting the need for further research to determine optimal treatment strategies.
CLINICAL CANCER RESEARCH
(2021)
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Article
Oncology
Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou
Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Akio Nakasya, Yuya Hagiwara, Tatsuki Ikoma, Yusuke Kurioka, Toshihiko Matsumoto, Yoshiyuki Yamamoto, Takao Tsuduki, Takeshi Kajiwara, Toshikazu Moriwaki, Tomohiro Nishina, Natsumi Yamashita, Ichinosuke Hyodo
Summary: This study compared the efficacy and toxicity of nab-PTX + RAM and PTX + RAM for the treatment of AGC using propensity score matching. The results showed that nab-PTX + RAM exhibited more favorable trends in terms of PFS and OS but was more myelosuppressive than PTX + RAM.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Genetics & Heredity
Seung Tae Kim, Jason K. Sa, Sung Yong Oh, Kyung Kim, Jung Yong Hong, Won Ki Kang, Kyoung-Mee Kim, Jeeyun Lee
Summary: The study identified a subset of GC patients with distinct clinical response to ramucirumab therapy through prospective molecular characterization. The results demonstrate the feasibility of personalized therapeutic opportunities in gastric cancer.
Article
Chemistry, Medicinal
M. Kimura, E. Usami, H. Teramachi, T. Yoshimura
Summary: This study found that grade ≥1 neutropenia and the number of anti-cancer drugs used were independently associated with survival in patients receiving paclitaxel plus ramucirumab as second line chemotherapy for advanced gastric cancer. Patients with grade ≥1 neutropenia had significantly prolonged treatment durations compared to those without, indicating potential benefits of this therapy for patients with initial neutropenia.
Article
Oncology
Sirui Tan, Jing Yu, Qiyue Huang, Nan Zhou, Hongfeng Gou
Summary: This retrospective analysis investigated the outcomes of PD-1 inhibitors combined with nab-paclitaxel-based chemotherapy as second-line therapy for advanced GBC. The results suggest that this treatment approach may be a potential option for GBC and further evaluation is warranted.
FRONTIERS IN ONCOLOGY
(2022)
Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Lorenzo Fornaro, Gianna Musettini, Paola Orlandi, Irene Pecora, Caterina Vivaldi, Marta Banchi, Francesca Salani, Elisabetta Fini, Valentina Massa, Silvia Catanese, Federico Cucchiara, Monica Lencioni, Gianluca Masi, Enrico Vasile, Guido Bocci
Summary: Ramucirumab plus paclitaxel is considered standard treatment for second-line gastric carcinoma (GC) patients. This study evaluated plasma VEGF-A, VEGF-D, and sVEGFR-2 as potential markers of resistance or response to this treatment. Results showed significant increases in VEGF-A and VEGF-D levels during treatment, and early increase in sVEGFR-2 levels was associated with longer progression-free survival and overall survival.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Rui-Hua Xu, Yanqiao Zhang, Hongming Pan, Jifeng Feng, Tao Zhang, Tianshu Liu, Yanru Qin, Shukui Qin, Xianli Yin, Baorui Liu, Yi Ba, Nong Yang, Pei Jye Voon, Suebpong Tanasanvimon, Chan Zhou, Wan Li Zhang, Lin Shen
Summary: The RAINBOW-Asia study conducted in China and other Asian countries showed that the combination of ramucirumab and paclitaxel is effective and safe for patients with advanced gastric or GEJ adenocarcinoma in the Asian population, predominantly Chinese, as a second-line treatment option.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Immunology
Ju-Li Lin, Jian-Xian Lin, Jun Peng Lin, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-bin Wang, Jun Lu, Qi-Yue Chen, Chang-Ming Huang
Summary: The study demonstrates that the combination of camrelizumab with nab-paclitaxel plus S-1 is safe and effective for the treatment of gastric cancer with serosal invasion. This treatment approach significantly improves tumor regression grade and the rate of pathologic complete response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jianzheng Wang, Yunduan He, Baiwen Zhang, Huifang Lv, Caiyun Nie, Beibei Chen, Weifeng Xu, Jing Zhao, Xiaojiao Cheng, Qingli Li, Shuiping Tu, Xiaobing Chen
Summary: Sintilimab combined with nab-paclitaxel as a second-line treatment for advanced gastric cancer/gastroesophageal junction cancer exhibits good anti-tumor activity and an acceptable safety profile, warranting further investigation and evaluation to identify more patients who can benefit from this combined treatment strategy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nan Zhou, Xiaofen Li, Yu Yang, Sirui Tan, Shunyu Zhang, Qiyue Huang, Hongfeng Gou
Summary: This clinical trial aims to evaluate the efficacy and safety of second-line sintilimab in combination with nab-paclitaxel in advanced biliary tract cancer patients. Additionally, the trial provides an opportunity for translational research.
Article
Oncology
L. A. Emens, S. Adams, C. H. Barrios, V Dieras, H. Iwata, S. Loi, H. S. Rugo, A. Schneeweiss, E. P. Winer, S. Patel, V Henschel, A. Swat, M. Kaul, L. Molinero, S. Patel, S. Y. Chui, P. Schmid
Summary: The study showed that although A + nP for first-line treatment of triple-negative breast cancer did not significantly improve overall survival in the overall population, clinically meaningful benefits were observed in patients with PD-L1 expression on tumor infiltrating immune cells. The combination therapy remained safe and tolerable with longer follow-up.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Gunn Huh, Hee Seung Lee, Jin Ho Choi, Sang Hyub Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Seungmin Bang, Eaum Seok Lee
Summary: In patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure, GnP demonstrated favorable efficacy with acceptable toxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Article
Surgery
Yosuke Minoda, Eikichi Ihara, Soichi Itaba, Yorinobu Sumida, Kazuhiro Haraguchi, Akira Aso, Takahiro Mizutani, Takashi Osoegawa, Mitsuru Esaki, Shuzaburo Nagatomo, Kei Nishioka, Kazumasa Muta, Xiaopeng Bai, Haruei Ogino, Nao Fujimori, Daisuke Tsurumaru, Kenoki Ohuchida, Hu Qingjiang, Eiji Oki, Hidetaka Yamamoto, Yoshihiro Ogawa
Summary: Mucosal incision-assisted biopsy (MIAB) is a safe procedure with minimal impact on postoperative prognosis for sampling gastric subepithelial lesions (SELs). MIAB releases some tumor cells after damaging the SEL's pseudocapsule, but it does not significantly affect the 5-year disease-free survival rate.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Article
Gastroenterology & Hepatology
Hajime Otsu, Sho Nambara, Qingjiang Hu, Yuichi Hisamatsu, Takeo Toshima, Kazuki Takeishi, Yusuke Yonemura, Takaaki Masuda, Eiji Oki, Koshi Mimori
Summary: The study aimed to identify individuals at high risk of gastric cancer by detecting microRNAs (miRNA) in the blood as biomarkers. Specific miRNA combinations may serve as promising biomarkers for precancerous lesions in gastric cancer.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
Article
Gastroenterology & Hepatology
Yoshiya Takahashi, Kenichi Hakamada, Hajime Morohashi, Harue Akasaka, Yuma Ebihara, Eiji Oki, Satoshi Hirano, Masaki Mori
Summary: This study aimed to validate the feasibility of telerobotic surgery by examining the communication environment and local/remote robot operation. The results showed that remote surgery was successful and comparable to local surgery, indicating that the system has the necessary technology for widespread social implementation.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
R. Nakanishi, K. Morooka, K. Omori
DISEASES OF THE COLON & RECTUM
(2023)
Article
Oncology
Sho Nambara, Takaaki Masuda, Kosuke Hirose, Qingjiang Hu, Taro Tobo, Yuki Ozato, Junji Kurashige, Yoshiki Hiraki, Yuichi Hisamatsu, Tomohiro Iguchi, Keish Sugimachi, Eiji Oki, Tomoharu Yoshizumi, Koshi Mimori
Summary: This study investigated the role of Rab27b in peritoneal metastasis (PM) of gastric cancer. The results showed that knockdown of Rab27b reduced exosome secretion from gastric cancer cells and inhibited tumor metastasis. Clinical data also demonstrated that high expression of Rab27b was associated with poor prognosis in gastric cancer patients.
CANCER GENOMICS & PROTEOMICS
(2023)
Article
Orthopedics
Yoshiya Takahashi, Kenichi Hakamada, Hajime Morohashi, Harue Akasaka, Yuma Ebihara, Eiji Oki, Satoshi Hirano, Masaki Mori
Summary: Telerobotic surgery requires certain network specification values to ensure acceptable levels of delay and degradation caused by video compression and restoration.
ASIAN JOURNAL OF ENDOSCOPIC SURGERY
(2023)
Article
Oncology
Yoshihiko Maehara, Eiji Oki, Mitsuhiko Ota, Norifumi Harimoto, Koji Ando, Ryota Nakanishi, Tetsuro Kawazoe, Yoshiaki Fujimoto, Kentaro Nonaka, Hiroyuki Kitao, Makoto Iimori, Kunio Makino, Teiji Takechi, Takeshi Sagara, Kazutaka Miyadera, Kazuaki Matsuoka, Hiroshi Tsukihara, Yuki Kataoka, Takeshi Wakasa, Hiroaki Ochiiwa, Yoshihiro Kamahori, Eriko Tokunaga, Hiroshi Saeki, Tomoharu Yoshizumi, Yoshihiro Kakeji, Ken Shirabe, Hideo Baba, Mitsuo Shimada
Summary: Professor Setsuro Fujii achieved significant results in drug discovery research, developing nine well-known drugs that include anticancer drugs and therapeutic drugs for various diseases. He brought hope to patients worldwide and continues to inspire ongoing drug discovery research.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yoichi Naito, Saori Mishima, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba
Summary: This article discusses the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors and provides 14 clinical recommendations for proper NTRK testing and treatment selection.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama, Motohiro Kato, Hirotsugu Kenmotsu, Yasuhiro Kodera, Keigo Komine, Takafumi Koyama, Osamu Maeda, Mitsuru Miyachi, Hiroshi Nishihara, Hiroyuki Nishiyama, Shouichi Ohga, Wataru Okamoto, Eiji Oki, Shigeru Ono, Masashi Sanada, Ikuo Sekine, Tadao Takano, Kayoko Tao, Keita Terashima, Katsuya Tsuchihara, Yasushi Yatabe, Takayuki Yoshino, Eishi Baba
Summary: The development of novel antitumor agents and biomarkers has improved survival in different tumor types. Immune checkpoint inhibitors have shown efficacy in patients with TMB-H solid tumors, leading to the need for guidelines prioritized for these patients. This guideline provides recommendations for properly testing TMB and selecting patients who can benefit from immunotherapy.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Summary: Adding panitumumab to standard first-line chemotherapy significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer, particularly in those with left-sided tumors.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Endocrinology & Metabolism
Kazuhiro Kai, Toshifumi Fujiwara, Yoshihiro Nagao, Eiji Oki, Tomoharu Yoshizumi, Masatoshi Eto, Yasuharu Nakashima
Summary: This study investigated the effects of sleeve gastrectomy on bone and psoas muscle density and cross-sectional area using retrospective clinical CT scans. The results showed that sleeve gastrectomy significantly improved anthropometric measures without causing changes in serum calcium and phosphorus levels. However, there was a significant decrease in the psoas muscle mass after surgery.
Article
Oncology
Shin Kobayashi, Hideaki Bando, Akinobu Taketomi, Takeshi Takamoto, Eiji Shinozaki, Manabu Shiozawa, Hiroki Hara, Kentaro Yamazaki, Koji Komori, Nobuhisa Matsuhashi, Takeshi Kato, Yoshinori Kagawa, Mitsuru Yokota, Eiji Oki, Keigo Komine, Shinichiro Takahashi, Masashi Wakabayashi, Takayuki Yoshino
Summary: This study aims to evaluate the efficacy and safety of a novel triplet regimen in the perioperative period for patients with resectable BRAF V600E mutant colorectal cancer. The triplet regimen includes encorafenib, binimetinib, and cetuximab, administered for 3 cycles each before and after curative resection. The primary endpoint is the 1-year progression-free survival rate, and secondary endpoints include disease-free survival, overall survival, and objective response rate.
Article
Gastroenterology & Hepatology
Yu Miyashita, Eiji Oki, Tomohiro Kamori, Yoshito Akagi, Shinichiro Mori, Norifumi Hattori, Kazuma Kobayashi, Mototsugu Shimokawa, Yoshinao Oda, Masaki Mori
Summary: This study investigated the effects of neoadjuvant chemotherapy on the tumor microenvironment of locally advanced rectal cancer and explored the potential of immune checkpoint inhibitors in MMR-deficient colorectal cancer. The results showed significantly increased expression levels of immune checkpoint molecules and tumor-infiltrating lymphocytes after neoadjuvant chemotherapy. Therefore, combined chemotherapy and immunotherapy may be effective in rectal cancer patients.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
Article
Gastroenterology & Hepatology
Yoshinori Kagawa, Jun Watanabe, Mamoru Uemura, Koji Ando, Akira Inoue, Koji Oba, Ichiro Takemasa, Eiji Oki
Summary: This study aimed to evaluate the feasibility and safety of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer (LARC) in Japan. The results showed satisfactory pathological complete response (pCR) and clinical complete response (cCR), as well as well-tolerated safety of TNT in LARC patients in Japan.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
Article
Oncology
Shinichiro Ikeda, Qingjiang Hu, Keita Natsugoe, Tomoya Harima, Yasushi Tanaka, Izumi Kinoshita, Kentaro Nonaka, Sho Nambara, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Yasue Kimura, Eiji Oki, Yoshinao Oda, Tomoharu Yoshizumi
Summary: This case report describes a rare case of primary adenocarcinoma of the duodenum with high microsatellite instability (MSI-H). The patient was diagnosed with Lynch syndrome, which is closely related to MSI-H. Pembrolizumab therapy was effective in treating the tumor.
INTERNATIONAL CANCER CONFERENCE JOURNAL
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)